In order to assess the methylation status of the EGFL7 promoter in glioma cells, several BTPCs as well as LN229 cells were treated with a combination of DNA methyltransferase inhibitor 5‐Aza‐dC (Aza) and histone deacetylase inhibitor 4‐phenylbutyric acid (PBA). Here, EGFL7 is linked to central nervous system cancer.